Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Myxofibrosarcoma”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Ended earlyNCT04996004
What this trial is testing

Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Who this might be right for
Leiomyosarcoma
Pfizer 76
Early research (Phase 1)Study completedNCT03009201
What this trial is testing

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Who this might be right for
Advanced Soft Tissue SarcomaLocally Advanced AngiosarcomaLocally Advanced Leiomyosarcoma+24 more
OHSU Knight Cancer Institute 16
Testing effectiveness (Phase 2)Ended earlyNCT02601209
What this trial is testing

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Who this might be right for
High Grade SarcomaMetastatic LeiomyosarcomaMetastatic Malignant Peripheral Nerve Sheath Tumor+16 more
National Cancer Institute (NCI) 151
Early research (Phase 1)Looking for participantsNCT05711615
What this trial is testing

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Who this might be right for
Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more
National Cancer Institute (NCI) 30